Powering What's Possible
Novavax (novavax.com) earns a Brand Analyzer score of 88 out of 100, placing it in the Strong Brand tier among Healthcare brands. Among 2859 Healthcare brands analyzed, Novavax ranks in the 98th percentile (category average 70, leader 96). The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark. Dimension scores: Name Quality 100/100, Digital Presence 100/100, Visual Identity 95/100, Messaging Clarity 95/100, Trust Foundation 100/100, AI Discoverability 68/100, Brand Authority 59/100.
Novavax is a biotechnology company headquartered in Gaithersburg, Maryland, founded in 1987. It develops protein-based vaccines using its proprietary Matrix-M adjuvant technology, working through strategic partnerships with healthcare organizations and governments. The company focuses on research and development of vaccine solutions aimed at protecting public health, positioning itself as a science-driven innovator in the biotech sector serving healthcare partners, governments, investors, and global populations.
| Brand Name | Novavax |
|---|---|
| Domain | novavax.com |
| Industry | Healthcare |
| Founded | 1987 |
| Headquarters | Gaithersburg |
| Main Competitors | Pfizer (89/100), Moderna (94/100), GSK (83/100), Sanofi (82/100), AstraZeneca (82/100), Merck (81/100), Johnson & Johnson (Janssen) (87/100) |
Moz Domain Authority 65/100 vs category average 32 / leader 95 - a strong backlink profile, so AI systems frequently encounter mentions of the brand.
Ranked #140,570 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
Novavax has a dedicated Wikipedia entity - a top-weighted signal AI models rely on to identify and describe the brand.
The homepage meta description reads "Novavax is a biotech company with a proven technology, focused on developing our R&D assets and establishing partnerships to help protect health." (Meta description: 22 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:image, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, Drupal.
Social footprint: verified profiles on X (Twitter), LinkedIn, Instagram, YouTube, GitHub; no detected presence on Facebook - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Novavax scores 57/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Novavax has a limited AI-visibility profile at 57/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is visibility (70/100) and its weakest is trust (30/100). It benefits from a recognised Wikipedia company entity, a Wikidata knowledge-graph entry and a global traffic rank of #140,570 (Tranco). The main gaps holding it back: thin schema.org structured data and no llms.txt to steer AI to its best pages. In a live check, Claude could already identify Novavax from memory (August 2026) - a sign these signals are paying off.
Live results from asking a general-purpose AI assistant about the brand, checked August 2026.
When asked "What is Novavax?", Claude could identify the brand as of August 2026. Novavax is a biotechnology company based in Maryland that develops vaccines using protein subunit technology combined with its proprietary Matrix-M adjuvant. It's best known for developing a COVID-19 vaccine as an alternative to the mRNA vaccines from Pfizer and Moderna, and also Best known for Its protein-based COVID-19 vaccine (Nuvaxovid) as a non-mRNA alternative.
When asked "Best brands similar to Novavax?", Claude would recommend Novavax as of August 2026. It's a notable name in vaccine development and a recognizable alternative to mRNA vaccine makers, so it would come up naturally in that context.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Novavax's main competitors include Pfizer (89/100), Moderna (94/100), GSK (83/100), Sanofi (82/100), AstraZeneca (82/100). These companies compete in the Healthcare space for similar customers, offering comparable products or services.
Sources: Brand Analyzer scan
Novavax and Moderna are competitors in Healthcare. Brand Analyzer scores Novavax at 88/100 and Moderna at 94/100. They target overlapping audiences; the right choice depends on your specific needs and priorities.
Sources: Brand Analyzer scan
Popular alternatives to Novavax include Pfizer (89/100), Moderna (94/100), GSK (83/100), Sanofi (82/100), AstraZeneca (82/100). Each is an established option in the Healthcare space; the best fit depends on your specific needs, budget, and required features.
Sources: Brand Analyzer scan
Novavax is a biotechnology company headquartered in Gaithersburg, Maryland, founded in 1987. It specializes in developing protein-based vaccines using its proprietary Matrix-M adjuvant technology.
Sources: Novavax official site
Novavax has moderate AI-search visibility, scoring 57/100 on Brand Analyzer's AI visibility composite (visibility 70, trust 30, recommendation 67). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Novavax official site
Novavax was founded in 1987. Novavax operates in the Healthcare category. It is analyzed by Brand Analyzer across seven brand dimensions and AI-search visibility.
Sources: Wikidata
Novavax is headquartered in Gaithersburg. Novavax operates in the Healthcare category.
Sources: Wikidata
Novavax develops vaccines based on protein technology combined with its proprietary Matrix-M adjuvant. It conducts research and development of vaccine candidates and forms partnerships with healthcare organizations and governments to advance and distribute these vaccines.
Sources: Novavax official site
Novavax scores 67/100 on Brand Analyzer's AI recommendation signal, indicating it is reasonably likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority; a Wikipedia presence helps.
Sources: Novavax official site
Novavax offers protein-based vaccines developed using its proprietary Matrix-M adjuvant technology. Its offerings stem from an R&D pipeline focused on vaccine development, delivered through partnerships with healthcare organizations and governments.
Sources: Novavax official site
Novavax can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Novavax official site
Novavax's offerings are used by healthcare partners, governments, investors, and global populations seeking vaccine solutions, according to the company's stated target audience.
Sources: Novavax official site
Novavax is known for its proprietary Matrix-M adjuvant technology and its protein-based vaccine platform, which it develops through R&D efforts and strategic partnerships with healthcare and government entities.
Sources: Novavax official site
Ranked closest to Novavax: LabVantage (88/100), Kaiser Permanente (88/100), Segal (88/100), Siemens Healthineers (88/100).
A step up - brands to learn from: Olay (91/100), Lionbridge (91/100).
Category leader: Elsevier (96/100).